Addex Pharmaceuticals
Investor PresentationJune 2010
Disclaimer
These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.
These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.
These materials are strictly confidential and must not be disclosed or distributed to third parties.
3
•Goal: allosteric modulators for human health
•Focus: CNS, metabolic disorders, inflammation
•Proprietary allosteric modulator discovery platform
•15 discovery/development programs
• Pharma validation– Partners: Johnson & Johnson and Merck & Co., Inc.
– Investors: SR-One (GSK) and Roche Venture Fund
•138 staff / founded 2002 in Geneva, Switzerland
The Company
4
Financials• Cash for operations through end of 2011
CHF76.6 million (€52m/US$71m) at end of 2009
• Market cap (25 May): CHF66.5m (€47m / US$57m)
• SIX Swiss Exchange: ADXN (ISIN:CH0029850754)
• 5,871,242 shares outstanding as of Dec 31, 2009
• Five analysts covering:
Piper Jaffray Sam Fazeli & Michael AitkenheadJefferies Peter Welford & Philippa GardnerHelvea Olav Zilian Bank Vontobel Andrew C. Weiss & Silvia SchanzBank am Bellevue Bob Pooler
Partner Phase IIPreclinical Phase I MilestoneLead
OptimizationHit-to-Lead
Assay Development &
Screening
Molecule / Mechanism
PIPELINE
Merck & Co., Inc.
Ortho-McNeil-Janssen
ADX68692FSHR NAM
ADX63365mGluR5 PAM
ADX71943GABA-B PAM
Start Ph I 4Q10
not disclosed
ADX71149mGluR2 PAM
Start Ph IIa2H10
Start Ph II 4Q10
Start Ph II 4Q10
Ortho-McNeil-JanssenStart Ph IIa
2H10
ADX48621mGluR5 NAM
NAM = negative allosteric modulator (an inhibitor) ‡ and undisclosed additional indications PAM = positive allosteric modulator (an activator) *
Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson subsidiary
Start Ph I 1Q11
Parkinson’s Disease Levodopa Induced Dyskinesia (PD-LID)
Dystonia
Schizophrenia
Anxiety
Osteoarthritic Pain
Schizophrenia ‡
Endometriosis / Benign Prostatic Hyperplasia
funded & developed by OMJPI*
funded & developed by OMJPI*
funded & developed by Merck
Partner Phase IIPreclinical Phase I MilestoneLead
OptimizationHit-to-Lead
Assay Development &
Screening
Molecule / Mechanism
DISCOVERY PROGRAMS
NAM = negative allosteric modulator (an inhibitor) ‡ and undisclosed additional indications PAM = positive allosteric modulator (an activator)
Inflammation
CNS
Metabolic Disorders
Merck & Co., Inc.
Alzheimer’s / Depression
Parkinson’s Disease ‡
DepressionPost Traumatic Stress Disorder
Sleep Disorders
Type II Diabetes
Type II Diabetes
Rheumatoid Arthritis, Psoriasis,
Alzheimer’s, Multiple Sclerosis
Psoriasis, Osteoarthritis
Gout, Type II Diabetes
funded by MerckmGluR4 PAM
GIPR PAM
TNFR1 NAM (CD120a)
GLP1 PAM
Orexin 2R NAM
mGluR7 NAM
mGluR2 NAM
A2A PAM
IL1R1 NAM (CD121a)
7
Partnered Programs
8
Agreement• With Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI)
– Utilize Addex platform to identify & develop orally available mGluR2 PAM for schizophrenia, anxiety and undisclosed indications• OMJPI funds collaboration on discovery & lead optimization• OMJPI funds & performs preclinical and clinical development
– Addex sits on oversight committees
ADX71149
Terms
• €3 million upfront
• Research funding to Addex during discovery collaboration (2005-2007)
• €112 in potential milestones upon completion of clinical and regulatory milestones
• Low double-digit royalties
9
Progress to Date
• Collaboration generated clinical candidates
– €4.2 million in R&D funding between 2005-2007
• Comprehensive Ph I program started in June 2009
– €1 million milestone paid upon initiation of Phase I
– More than 5 Phase I trials in healthy volunteers• SAD, MAD
• Food & gender
• Ketamine challenge (schizophrenia model)
• Anxiety challenge
• Phase II program scheduled to start in 2010
– schizophrenia
– anxiety
– potentially other indicationsNote
mGluR2 activation is clinically validated in anxiety & schizophrenia
ADX71149
* Nature Medicine 2007: http://bit.ly/bbnsyQ
10
ADX63365
Agreement
• Merck & Co., Inc. licensed Addex mGluR5 PAMs in 2008
• mGluR5 PAM expected to be highly differentiated– Merck already had demonstrated mGluR5 PAM have efficacy in
animal models of schizophrenia
– Preclinical data show efficacy for cognitive deficit (& psychosis)
– Despite efficacy of marketed drugs many schizophrenia patients remain unable to learn new skills to support themselves
– FDA has recognized cognitive deficit as an unmet medical need in schizophrenia
• Merck is responsible for development of ADX63365 & backups
Terms
• $22 million upfront
• $680 million in milestones
• Undisclosed royalties
11
Progress
• Deal signed (Dec 07)
• 1st Preclinical milestone (Feb 08)– $250,000
• 2nd preclinical milestone (Jul 09)– $500,000
– Orally available mGluR4 PAM showed efficacy in model of PD
• Collaboration extended (Dec 09)– Merck commits $1.8 million in research funding
– Going forward all costs transferred to Merck
Agreement
• Discover and develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAM) with Merck & Co., Inc.
• The deal includes mGluR4 PAM leads already discovered by Addex
• Merck is responsible for preclinical and clinical development
• Addex will sit on oversight committees Terms
• $3 million upfront
• $167.5 million in potential milestones
• Annual tech access fee $250,000
• Research funding 2009/2010
• Undisclosed royalties
• Option to co-promote in EU
mGluR4 PAM
12
Platform Revenues
Partner Product Indication(s)Status
at signingStatus April
30, 2010Upfront
Cash
Milestones or R&D funding
received
Total Potential
Milestones
Ortho-McNeil-Janssen
Pharmaceuticals, Inc.mGluR2 PAM
ADX71149 Anxiety &
schizophreniaHit-to-Lead
(Dec 2004)Phase I €3 million €5.2 million €112 million
Merck & Co., Inc. mGluR4 PAMParkinson’s
diseaseHit-to-Lead
(Dec 2007)
preclinical efficacy in PD model
$3 million $2.5 million $167.5 million
Merck & Co., Inc.mGluR5 PAM
ADX63365 schizophrenia
Clinical Candidate
(Jan 2008)
not disclosed
$22 million n.a. $680 million
Proprietary Platform Revenues
• Addex has received partnering revenue every year since 2004
• Cash inflows generated to date: CHF43 million
• All three partnerships are fully funded by our partners
• Potential for up to about $1 billion in milestones plus royalties
* and undisclosed indications
13
Wholly Owned Programs
14
ADX48621 Overview
• Phase I completed– Three studies: SAD, MAD, gender & food effects
– 110 patients treated to date, including older volunteers
– Safety & tolerability justify further clinical study
• Differentiated– Only product shown to reduce dystonia in MPTP model
– Chemical series unrelated to other mGluR5 NAMUnique metabolic profile
– NCE patents valid through 2025 in most territories
– Unrelated series of backup molecules in clinical candidate selection
15
•ADX48621 effects in HIC model suggestIt should be tested further as a potential drug for PD It has potential to be a dopamine sparing agent
ADX48621 efficacy in HIC model• Haloperidol induced catalepsy (HIC) is a preclinical model of PD
ADX48621 dose-dependently reversed HIC in 3 independent experimentsMTEP mGluR5 antagonist is well documented to work in the HIC model
0
10
20
30
40
50
60
70
80
90
Vehicle ADX48621, 1mg/kg
ADX48621, 3mg/kg
ADX48621, 10mg/kg
ADX48621, 30mg/kg
MTEP, 30mg/kg
Late
ncy
(sec)
1st experiment2nd experiment3rd experiment
***
*********
****
***
**
***
+ 1 mg/kg haloperidol
**p<0.01, ***p<0.001 versus vehicle group
16
MPTP model of PD-LID
What is the MPTP Model?
• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
– Neurotoxin destroys dopaminergic neurons
– Symptoms similar to PD, treatable with levodopa
• MPTP monkeys develop levodopa induced dyskinesia (LID), including both chorea (trembling) and dystonia (cramping) seen in humans
• MPTP PD-LID model is predictive of efficacy in humans
– KOLs consider it among the most translational models in the CNS space
– AFQ056 (mGluR5/Novartis) showed efficacy in MPTP PD-LID model
– AFQ056 showed efficacy in Phase IIa PD-LID trial
17
• ADX48621 or vehicle administered 30 min prior to levodopa
• Behavioral assessment began upon levodopa administration – trained observers performed video review
– dyskinesia & PD disability scoring (10 min every 30 min for 2hrs)
lower scores (left axis) indicate fewer symptoms/disabilitydyskinesia symptoms are side effects from levodopadisability is a measure of Parkinson’s disease severity
ADX48621 MPTP Study Design
18
ADX48621 reduced dyskinesia without compromising levodopa efficacy
0
5
10
15
L-DOPA (100%)
vehicle
ADX48621 (mg/kg)
3 10 30
*
dysk
ines
ia (
0-2
hr)
ADX48621 dose-dependently reduced dyskinesia
(chorea + dystonia)
Dyskinesia
ADX48621 efficacy in MPTP model
0 60 120 180 240
vehicle
none
mild
moderate
marked
severe
+ L-DOPA
ADX48621 (30 mg/kg)
ADX48621 (3 mg/kg)ADX48621 (10 mg/kg)
time (mins)
dis
ab
ilit
y
ADX48621 does not reduce levodopa efficacy
Disability
+ levodopa
19
ADX48621 is the first drug-candidate known to have efficacy on dystonia
0
5
10
15
L-DOPA (100%)
vehicle
ADX48621 (mg/kg)
3 10 30
*
dys
ton
ia (
0-2
hr)
Dystonia
Dystonia = sustained muscle contractions (e.g. cramps)
0
5
10
15
L-DOPA (100%)
vehicle
ADX48621 (mg/kg)
3 10 30
**
chor
ea (
0-2
hr)
Chorea
Chorea = involuntary
movements (e.g. trembling)
ADX48621 efficacy in MPTP model
20
ADX48621development plan
• PD-LID: Study ADX48621-201– U.S. & EU Phase II trial in about 140 PD-LID patients – Double-blind, placebo-controlled, two doses of ADX48621– 6 weeks treatment– Endpoints: multiple instruments (in consultation with KOLs)– Start 4Q2010– Report data end 2011 or early 2012
• Dystonia: Study ADX48621-202– EU Phase IIa trial in about 32 dystonia patients– Double-blind, placebo-controlled, two-way crossover (two dose groups)– 2 week treatment period– Endpoints: multiple instruments (in consultation with KOLs)– Start 4Q2010 – Report data end 2011 or early 2012
21
ADX48621Commercial Potential
• Levodopa induced dyskinesia (LID) and dystonia are an unmet medical needs– Most Parkinson’s disease (PD) patients develop LID
– no drugs specifically approved for PD-LID – growing unmet medical need– PD-LID/dystonia is a faster path to market than PD
• Addex can retain co-promotion rights– treated by specialists– geographic split possible– mGluR4 PAM & mGluR2 NAM represent potential additions to future
neurodegenerative disease franchise
22
ADX71943
• ADX71943 is a gamma-aminobutyric acid subtype B (GABAB)receptor PAM
–Clinically/commercially validated mechanismgeneric GABAB agonist, baclofen, is marketed
other orthosteric GABAB agonists are clinically validated
–ADX71943 is differentiatedADX71943 is the only allosteric modulator of GABAB in development
Demonstrated analgesic effects in three preclinical pain models Potential for chronic pain (e.g. osteoarthritis) and other indications
• Phase I to start 4Q10
• ADX71943 is available for partnering
23
ADX71943 analgesic-like effects in preclinical models
Analgesic-like effect of ADX71943 in the CFA* model in rats after oral administration
ADX71943 caused a dose-dependent increase in the withdrawal threshold in the CFA induced mechanical hypersensitivity test in rats, with a minimum effective dose of 10 mg/kg p.o.
non-CFA CFA 1 hr 2 hr0
5
10
15
20
25
*****
Time post-dose (hr)
Wit
hd
raw
al T
hre
sho
ld
Vehicle
1 mg/kg ADX-71943
3 mg/kg ADX-71943
10 mg/kg ADX-71943
30 mg/kg ADX-71943
30 mg/kg Naproxen
Analgesic-like effect in the writhing test of oral ADX71943 in mice
ADX71943 caused a dose-dependent reduction of acetic acid-induced writhing in mice with a minimum effective dose between 3 and 10 mg/kg p.o.
*p<0.05, **p<0.01, ***p<0.001 vs. JQ-02 vehicle; +++p<0.001 vs. 1%CMC vehicle
Experiment 1Experiment 2Experiment 3Experiment 4
vehicle
Nu
mb
er
of
wri
the
s
0
24
6
810
1214
16
1820
22
0.3 1 3 10 30 100 3
+++****** ***
***
*
** ***
*
mg/kgmg/kg
AD
X71
943
Bac
lofe
n
ADX71943 Baclofen
*CFA = Complete Freund's Adjuvant
24
ADX68692
Roles of FSH/LH
Females
• FSH involved in folliculogenesis– maturation of follicles
– estrogen production
• LH triggers ovulation, progesterone
Males
• FSH supports spermatogenesis
• LH stimulates testosterone production
Status
• ADX68692 is a follicle stimulating hormone receptor (FSHR) NAM
• Orally available non-steroidal molecule with drug-like characteristics
• In late preclinical development
• ADX68692 is available for partneringPreclinical Data & Potential Indications
• Statistically significant reduction in testosterone & prostate weight Benign prostatic hyperplasia (BPH)
• Statistically significant reduction in estradiol Endometriosis
25
Allosteric ModulatorDiscovery & Optimization
26
Allosteric Modulation
Because they bind a different site on the receptor, allosteric modulators do not turn receptors on or off the way the body’s natural activators and most drugs do. Instead, they act more like a dimmer switch, offering control over the ease & intensity of (de-)activation while allowing the body to retain its natural control over initiating receptor activation via the active site (e.g. the on/off switch).
27
Allosteric Advantages
• Greater specificity than orthosteric molecules – e.g. mGluRs
• Can target receptors considered “intractable” or only tractable by biologics, peptides or proteins
– e.g. GLP-1
• Non-competitive mechanism–Un-exploited intellectual property–Less dose related toxicity
•Acts like a dimmer not “on/off” switch–Body maintains control of receptor activation cycle
Natural ligand
Time
PAM + natural ligand
NAM + natural ligand
Bio
log
ical
res
po
nse
Allostery preserves natural rhythm
Time
Natural ligand
Agonist
Antagonist
Bio
log
ical
res
po
nse
Orthosterics are steady state
28
Serendipity has yielded some marketed allosteric modulators. Most recent examples include:
• Sensipar/Mimpra cinacalcet (Amgen) – Positive allosteric modulator (PAM) of calcium sensing receptor– Approved 2004– treats secondary hyperparathyroidism
• Selzentry/Celsentri maraviroc (Pfizer) – Negative allosteric modulator (NAM) of CCR5– Approved 2007– Treats CCR5-tropic HIV-1
Allosteric Modulators 101
29
• Allosteric modulators are hard to find– Industrial tools for orthosteric drugs are not appropriate – Pharma has been focused on tools for finding orthosteric drugs– Why didn’t pharma industrialize allosteric drug discovery?
• Upfront investment to build allosteric drug discovery platform was high
• Time to value creation was long & uncertain
• Addex is industrializing allosteric modulation discovery– Proprietary assays
• High throughput screening & optimization tools (384 well plates & robotics)
• Direct detection systems – proximal to target – continuous real-time observation– works for molecules (i.e. allosteric modulators) that do not activate target receptor
– Allostery biased library of over 70,000 compounds
The Addex raison d'être
30
Proprietary Screening AssaysG-Protein Coupled Receptors
• Phoenyx– a cAMP dynamic non stop assay
• FBBA (GLP1R, mGluR7)– Fluorescence-Based Binding Assay – Measures bi-molecular interactions
• Proxylite (GLP1R, GIP)– Proximal & dynamic assays for functional measurements of
all types of GPCRs
31
• APRA (TNFR1)–Accessory Protein Relocalization Assays
• ADX-tags series 1 (IL1R) –Proximal & dynamic assays for functional measurements –Measures activation-dependent association or dissociation of
binding partners
• ADX-tags series 2 (TNFR1, IL1R)–measures conformational changes that lead to activation signal–measures multimerization changes that lead to activation signal
Proprietary Screening Assaystype 1 single-pass transmembrane proteins
32
Allostery Biased Library in-silico analysis
Addex library and marketed drugs share the same physicochemical property space BUT Addex library occupies a unique structural space
Addex library and marketed drugs share the same physicochemical property space BUT Addex library occupies a unique structural space
Physicochemical Comparison Structural Comparison
Addex CompoundsMarketed Drugs
Addex CompoundsMarketed Drugs
33
Platform Validation
• Addex identified selective orally available small molecules for– Challenging GPCRs (mGluRs, GABA-B & A2A)– Peptide receptors (GLP1R, GIPR)– Cytokine receptors (TNFR1 & IL1R1)
• The proof is in the pudding – Merck & Co., Inc. licensed mGluR4 PAM & mGluR5 PAM– Johnson & Johnson licensed mGluR2 PAM
34
Summary
• 15 Programs for High Value Targets/Indications–Highly differentiated allosteric mechanism
–Low target related risk (i.e. mostly clinically validated targets)
• Allosteric Modulator Platform–Proprietary tools + tailored library
–Platform + multi-disciplinary approach are scalable
• 3 Validating Partnerships (MRK/J&J)
• Top Tier Investors
• Cash to end of 2011
35
Management & Boards
Vincent Mutel, Chief Executive Officer Tim Dyer, Chief Financial Officer Charlotte Keywood, Chief Medical Officer Sonia Poli, Head of Non-Clinical Development Laurent Galibert, Head of Inflammation & Metabolic Disorders
Board of Directors
André J. Mueller, Chairman
Vincent Mutel, Vice Chairman & CEO of Addex
Andrew Galazka, SVP Scientific Affairs, Merck-Serono
Ray Hill, former Head of EU Licensing, Merck & Co., Inc.
Vincent Lawton, former MD of Merck Sharp & Dohme U.K.
Beat E. Lüthi, CEO of CTC Analytics
Antoine Papiernik, Sofinnova Partners
Scientific Advisory Board
George F. Koob, Ph.D., Chairman
Bernhard Bettler, Ph.D.
Arthur Christopoulos, Ph.D.
Patrick M. Sexton, Ph.D.
Mark A. Geyer, Ph.D.
Barbara J. Mason, Ph.D.
Jean-Philippe Rocher, Head of Core Chemistry Robert Lütjens, Head of Core Biology Tatiana Carteret, Head of Human Resources
Chris Maggos, Investor Relations & Communications
Executive Management
36
www.addexpharma.com
allosteric modulators for human health
Top Related